The protective efficacy of polyvalent pneumococcal polysaccharide vaccine

New England Journal of Medicine

Volumn 325, Issue 21, 1991, Pages 1453-1460

  Shapiro, Eugene D ^a   Berg, Anne T ^a   Schroeder, Donna ^a   Parcells, Valerie ^a   Margolis, Amy ^a   Adair, Russell K ^a   Austrian, Robert ^b   Clemens, John D ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPETENCE; INFECTION; MAJOR CLINICAL STUDY; MINER; PRIORITY JOURNAL; PROTECTION; SEROTYPING; STATISTICAL ANALYSIS; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADOLESCENT; ADULT; AGED; BACTERIAL VACCINES; CASE-CONTROL STUDIES; FEMALE; HUMAN; MALE; MIDDLE AGE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROSPECTIVE STUDIES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VACCINATION;

EID: 0026042704     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199111213252101     Document Type: Article

References (38)

1. Pneumococcal polysaccharide vaccine. MMWR 1978; 27: 25–31.
2. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977; 238: 2613–6.
3. Austrian R, Douglas RM, Schiffman G, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976; 89: 184–94.
4. American College of Physicians. Pneumococcal vaccine recommendation. Ann Intern Med 1982; 96: 206–7.
5. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980; 303: 549–52.
6. Giebink GS, Schiffman G, Krivit W, Quie PG. Vaccine-type pneumococcal pneumonia after vaccination in an asplenic patient. JAMA 1979; 241: 2736–7.
7. Ahonkhai VI, Landesman SH, Fikrig SM, et al. Failure of pneumococcal vaccine in children with sickle-cell disease. N Engl J Med 1979; 301: 26–7.
8. Clemens JD, Shapiro ED. Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials? Rev Infect Dis 1984; 6: 589–600.
9. Schwartz JS. Pneumococcal vaccine: clinical efficacy and effectiveness. Ann Intern Med 1982; 96: 208–20.
10. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF III. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986; 104: 1–6.
11. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315: 1318–27.
12. Shapiro ED. Pneumococcal vaccine failure. N Engl J Med 1987; 316: 1272–3.
13. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987; 83: 425–30.
14. Sims RV, Steinmann WC, McConville JH, King LK, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108: 653–7.
15. Erratum, Ann Intern Med 1988; 109: 762–3.
16. Gaillat J, Zmirou D, Mallaret MR, et al. Essai clinic du vaccin antipneumococcique chez des personne agees vivant en institution. Rev Epidemiol Sante Publique 1985; 33: 437–44.
17. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk for serious pneumococcal infections. Ann Intern Med 1984; 101: 325–30.
18. Riley ID, Lehmann D, Alpers MP, Marshall TF, Gratten H, Smith D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua, New Guinean children. Lancet 1986; 2: 877–81.
19. Austrian R. A reassessment of pneumococcal vaccine. N Engl J Med 1984; 310: 651–3.
20. Austrian. The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med 1976; 43: 699–709.
21. Henrichsen J. The pneumococcal typing system and pneumococcal surveillance. J Infect 1979; 1: Suppl 2: 31–7.
22. Update: pneumococcal vaccine usage — United States. MMWR 1984; 33: 273–6, 281.
23. Robbins JB, Austrian R, Lee C-J, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148: 1136–59.
24. Fleiss JL. Statistical methods for rates and proportions. New York: Joseph L. Wiley, 1981.
25. Schlesselman JJ. Case–control studies: design, conduct, analysis. New York: Oxford University Press, 1982.
26. Aitkin M, Anderson D, Francis B, Hinde J. Statistical modelling in GLIM. New York: Oxford University Press, 1989.
27. Halloran ME, Haber M, Longini IM Jr, Struchiner CJ. Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 1991; 133: 323–31.
28. Bliss EA, McClasky WD, Long PH. A study of pneumococcus carriers. J Immunol 1934; 27: 95–103.
29. Webster LT, Hughes TP. The epidemiology of pneumococcus infection. J Exp Med 1931; 53: 535–52.
30. Austrian R. Pneumococcal infections. In: Germanier R, ed. Bacterial vaccines. New York: Academic Press, 1984:279–80.
31. Willems JS, Sanders CR, Riddiough MA, Bell JC. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980; 303: 553–9.
32. Patrick KM, Woolley FR. A cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA 1981; 245: 473–7.
33. Sisk JE, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986; 104: 79–86.
34. Fedson DS. Hospital-based pneumococcal immunization: the epidemiologic rationale and its implications. Infect Control 1982; 3: 303–8.
35. Fedson Influenza and pneumococcal immunization strategies for physicians. Chest 1987; 91: 436–43.
36. Lin KT, Lee CJ. Immune response of neonates to pneumococcal polysaccharide-protein conjugate. Immunology 1982; 46: 333–42.
37. Schneerson R, Robbins JB, Chu C, et al. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun 1984; 45: 582–91.
38. Schneerson R, Robbins JR, Parke JC Jr, et al. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun 1986; 52: 519–28.